↓ Skip to main content

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

Overview of attention for article published in Molecular Neurodegeneration, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 721)
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
3 news outlets
patent
1 patent

Citations

dimensions_citation
107 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Published in
Molecular Neurodegeneration, March 2015
DOI 10.1186/s13024-015-0008-9
Pubmed ID
Authors

Markus Mandler, Elvira Valera, Edward Rockenstein, Michael Mante, Harald Weninger, Christina Patrick, Anthony Adame, Sabine Schmidhuber, Radmila Santic, Achim Schneeberger, Walter Schmidt, Frank Mattner, Eliezer Masliah

Abstract

Multiple system atrophy (MSA) is a neurodegenerative disease characterized by parkinsonism, ataxia and dysautonomia. Histopathologically, the hallmark of MSA is the abnormal accumulation of alpha-synuclein (α-syn) within oligodendroglial cells, leading to neuroinflammation, demyelination and neuronal death. Currently, there is no disease-modifying treatment for MSA. In this sense, we have previously shown that next-generation active vaccination technology with short peptides, AFFITOPEs®, was effective in two transgenic models of synucleinopathies at reducing behavioral deficits, α-syn accumulation and inflammation. In this manuscript, we used the most effective AFFITOPE® (AFF 1) for immunizing MBP-α-syn transgenic mice, a model of MSA that expresses α-syn in oligodendrocytes. Vaccination with AFF 1 resulted in the production of specific anti-α-syn antibodies that crossed into the central nervous system and recognized α-syn aggregates within glial cells. Active vaccination with AFF 1 resulted in decreased accumulation of α-syn, reduced demyelination in neocortex, striatum and corpus callosum, and reduced neurodegeneration. Clearance of α-syn involved activation of microglia and reduced spreading of α-syn to astroglial cells. This study further validates the efficacy of vaccination with AFFITOPEs® for ameliorating the neurodegenerative pathology in synucleinopathies.

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Costa Rica 1 <1%
Unknown 98 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 25 25%
Researcher 20 20%
Student > Bachelor 15 15%
Student > Master 11 11%
Other 5 5%
Other 11 11%
Unknown 14 14%
Readers by discipline Count As %
Neuroscience 20 20%
Biochemistry, Genetics and Molecular Biology 16 16%
Agricultural and Biological Sciences 14 14%
Medicine and Dentistry 11 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 14 14%
Unknown 21 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2020.
All research outputs
#1,042,528
of 18,659,856 outputs
Outputs from Molecular Neurodegeneration
#50
of 721 outputs
Outputs of similar age
#16,701
of 233,628 outputs
Outputs of similar age from Molecular Neurodegeneration
#1
of 1 outputs
Altmetric has tracked 18,659,856 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 721 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,628 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them